Cited by 491Antifungal resistance and susceptibilityFungal Infections and StudiesFungal Plant Pathogen Control

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Open access

Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., McNicholas, P. M.·2006·Antimicrobial Agents and Chemotherapy

DOI 10.1128/aac.00163-06

Open this paper in CoChat — free account

Abstract

The in vitro activity of the novel triazole antifungal agent posaconazole (Noxafil; SCH 56592) was assessed in 45 laboratories against approximately 19,000 clinically important strains of yeasts and molds. The activity of posaconazole was compared with those of itraconazole, fluconazole, voriconazole, and amphotericin B against subsets of the isolates. Strains were tested utilizing Clinical and Laboratory Standards Institute broth microdilution methods using RPMI 1640 medium (except for amphotericin B, which was frequently tested in antibiotic medium 3). MICs were determined at the recommended endpoints and time intervals. Against all fungi in the database (22,850 MICs), the MIC(50) and MIC(90) values for posaconazole were 0.063 microg/ml and 1 mug/ml, respectively. MIC(90) values against all yeasts (18,351 MICs) and molds (4,499 MICs) were both 1 mug/ml. In comparative studies against subsets of the isolates, posaconazole was more active than, or within 1 dilution of, the comparator drugs itraconazole, fluconazole, voriconazole, and amphotericin B against approximately 7,000 isolates of Candida and Cryptococcus spp. Against all molds (1,702 MICs, including 1,423 MICs for Aspergillus isolates), posaconazole was more active than or equal to the comparator drugs in almost every category. Posaconazole was active against isolates of Candida and Aspergillus spp. that exhibit resistance to fluconazole, voriconazole, and amphotericin B and was much more active than the other triazoles against zygomycetes. Posaconazole exhibited potent antifungal activity against a wide variety of clinically important fungal pathogens and was frequently more active than other azoles and amphotericin B.

Integrity signals

Registry

Crossref · 10.1128/aac.00163-06

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736
Heart-Lung Transplantation
Yarbrough, W. M., Robbins, R. C., & Mallidi, H. R. (2016) · CRC Press eBooks · doi:10.3109/9781439802571-25 · Cited by 2,161
Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Beck‐Sagué, C. M., Jarvis, W. R., & System, N. N. I. S. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784
Trends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980–1997
McNeil, M. M., Nash, S. L., Hajjeh, R. A., Phelan, M. A., Conn, L. A., Plikaytis, B. D., & Warnock, D. W. (2001) · Clinical Infectious Diseases · doi:10.1086/322606 · Cited by 657
Posaconazole Is Effective as Salvage Therapy in Zygomycosis: A Retrospective Summary of 91 Cases
van Burik, J. H., Hare, R. S., Solomon, H. F., Corrado, M. L., & Kontoyiannis, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/500212 · Cited by 614
Posaconazole as Salvage Therapy for Zygomycosis
Greenberg, R. N., Mullane, K. M., van Burik, J. H., RAAD, I. I., Abzug, M. J., Anstead, G. M., Herbrecht, R., Langston, A. A., Marr, K. A., Schiller, G. J., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.126-133.2006 · Cited by 552
Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States
Ostrosky‐Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N. E., Kauffman, C. A., Cleary, J. D., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3149-3154.2003 · Cited by 494
History of the development of azole derivatives
Maertens, J. A. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00841.x · Cited by 487
Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000
Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.1032-1037.2002 · Cited by 405

Flagged first, then by citations

Show all 38 references

1 of the 38 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Yasuda, J. M. 2001. An update on antifungal therapy: a focus on systemic agents for invasive fungal infections. Calif. J. Health-Syst. Pharm.13:4-12.

Sorted by citations

Items 301–400 of 490

Genetic relatedness and antifungal susceptibility profile ofCandida albicansisolates from fungaemia patients
Costa‐de‐Oliveira, S., Sousa, I., Correia, A., Sampaio, P., Pais, C., Rodrigues, A. G., & Pina‐Vaz, C. (2010) · Medical Mycology · doi:10.3109/13693786.2010.511633 · Cited by 9
Model‐Informed Dose Justifications of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal Infection
Iwasa, T., de Almeida, C., Fauchet, F., Winchell, G. A., de Greef, R., Hasegawa, C., Yoshitsugu, H., & Wrishko, R. E. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2180 · Cited by 9
Safety of posaconazole
Jacinto, P. L., & Chandrasekar, P. H. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.765857 · Cited by 9
“The drug has excellent antifungal activity, both in vitro and in vivo, against Cryptococcus neoformans, Aspergillus spp., mucorales and endemic fungi, including Blastomyces [11-13].”
Background
New developments in the antifungal susceptibility testing of Candida
Pfaller, M. A. (2008) · Current Fungal Infection Reports · doi:10.1007/s12281-008-0019-x · Cited by 9
Zygomycosis Caused by Rhizopus microsporus and Rhizopus oryzae in Madhya Pradesh (M.P.) Central India: A Report of Two Cases
Nawange, S. R., Singh, S., Naidu, J., Jain, S. K., Nagpal, T., Behrani, D. S., Mellado, E., & Tudela, J. L. R. (2012) · Mycopathologia · doi:10.1007/s11046-012-9532-0 · Cited by 8
“[22] and Pfaller and Diekema [23].”
In vitro susceptibility of aflatoxigenic and non-aflatoxigenic Aspergillus flavus strains to conventional antifungal agents.
Fattahi, A., Zaini, F., Kordbacheh, P., Hashemi, S. J., Mahmoudi, M., & Safara, M. (2012) · PubMed · Cited by 8
Candidiasis in Pediatrics; Identification and In vitro Antifungal Susceptibility of the Clinical Isolates.
Mohammadi, R., & Ataei, B. (2016) · PubMed Central · Cited by 8
Cunninghamella bertholletiae Infection in a HLA-Haploidentical Hematopoietic Stem Cell Transplant Recipient with Graft Failure: Case Report and Review of the Literature
Luo, C., Wang, J., Hu, Y., Luo, Y., Tan, Y., Jin, A., Wei, B., Hu, H., & Huang, H. (2016) · Mycopathologia · doi:10.1007/s11046-016-0030-7 · Cited by 8
Antifungal Susceptibility of Candida albicans Isolates at a Tertiary Care Hospital in Bulgaria
Hitkova, H. Y., Georgieva, D. S., Hristova, P. M., & Sredkova, M. (2019) · Jundishapur Journal of Microbiology · doi:10.5812/jjm.92079 · Cited by 8
“The current data are similar to those reported worldwide (17, 22, 24, 30, 32, 41).”
Result
Infektionen des ZNS beim immuninkompetenten Patienten
Schmutzhard, E., & Pfausler, B. (2008) · Der Nervenarzt · doi:10.1007/s00115-008-2462-x · Cited by 8
Molecular identification, phylogeny and antifungal susceptibilities of dematiaceous fungi isolated from human keratomycosis
Mythili, A., Shobana, C. S., Krizsán, K., Hassan, A. S., Sangeetha, A. B., Homa, M., Papp, T., Alharbi, R., Othaim, A., Baazeem, A., et al. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.11.018 · Cited by 7
Posaconazole prophylaxis in neutropenic patients with hematological malignancies: limits in clinical practice
Bourdelin, M., Grenouillet, F., Daguindau, É., Muret, P., Desbrosses, Y., Dubut, J., Deconinck, É., Limat, S., & Larosa, F. (2014) · Medical Mycology · doi:10.1093/mmy/myu042 · Cited by 7
“For some years, a new generation of oral azoles, PSZ in particular, has shown activity against a wide spectrum of medically relevant fungi, including species of Candida, Aspergillus, Mucorales, and Fusarium [15,16].”
Background
Efficacy and Safety of Posaconazole in Hematopoietic Stem Cell Transplantation Patients with Invasive Fungal Disease
Zhang, S., He, Y., Jiang, E., Wei, J., Yang, D., Zhang, R., Zhai, W., Zhang, G., Wang, Z., Zhang, L., et al. (2017) · Future Microbiology · doi:10.2217/fmb-2017-0131 · Cited by 7
Early Therapeutic Drug Monitoring of Posaconazole Oral Suspension in Patients With Hematologic Malignancies
Suh, H. J., Kim, I., Cho, J., Park, S., Yoon, S. H., Hwang, J., Bae, J. Y., Lee, J., Koh, Y., Song, K., et al. (2017) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000469 · Cited by 7
In vitro Evaluation of the Effects of Fluconazole and Nano-Fluconazole on A. flavus and Aspergillus fumigatus Isolates
Sarrafha, M. R., Hashemi, S. J., Rezaei, S., & Bayat, M. (2018) · Jundishapur Journal of Microbiology · doi:10.5812/jjm.57875 · Cited by 7
Evaluation of Posaconazole Dosing in Children and Young Adults: A Single-Center Review
Garner, L. M., Ngo, S., Kaplan, J. B., Wilson, W. S., & McKinzie, C. J. (2021) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-26.8.834 · Cited by 7
Chemical and biological aspects of posaconazole as a classic antifungal agent with non-classical properties: highlighting a tetrahydrofuran-based drug toward generation of new drugs
Dadashpour, S., Ghobadi, E., & Emami, S. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02901-2 · Cited by 7
“dominantly unchanged (77%) in the feces and smaller amounts in the urine [31, 35, 37].”
Background
Analysis of molecular resistance to azole and echinocandin in Candida species in patients with vulvovaginal candidiasis
Lotfali, E., Erami, M., Fattahi, A., Nemati, H., Ghasemi, Z., & Mahdavi, E. (2022) · Current Medical Mycology · doi:10.18502/cmm.8.2.10326 · Cited by 8
“albicans (5 ́- GAAATCGGCATAT GCTGTGTC -3 ́) FKS 1-R- albicans (5 ́- AATGAACGACCAATGGAG AAG -3 ́) [21] primers with the following program: 5”
Method
Infections Caused by Candida krusei in Five Transplant and Two Surgical Patients
Bonatti, H., Stelzmueller, I., Berger, N., Lechner, M., Grif, K., Geltner, C., Margreiter, R., & Lass‐Flörl, C. (2009) · Surgical Infections · doi:10.1089/sur.2008.073 · Cited by 7
“All three patients had been receiving ﬂuconazole prophylaxis; changeover of the prophylaxis protocol to one of the newer antifungal agents with activity against Ck may be necessary during outbreaks of non-albicans Candida [32–35].”
Antifungal therapy in children: an update
Cecinati, V., Guastadisegni, C., Russo, F. G., & Brescia, L. P. (2012) · European Journal of Pediatrics · doi:10.1007/s00431-012-1758-9 · Cited by 7
Pyrrolo[1,2-α][1,4]benzodiazepines show potent in vitro antifungal activity and significant in vivo efficacy in a Microsporum canis dermatitis model in guinea pigs
Paulussen, C., de Wit, K., Boulet, G., Cos, P., Meerpoel, L., & Maes, L. J. R. M. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku034 · Cited by 7
Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.
Cojutti, P. G., Lugano, M., Righi, E., Rocca, G. D., Bassetti, M., Hope, W. W., & Pea, F. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2526-1 · Cited by 7
Posaconazole Oral Suspension as Salvage Therapy for Invasive Fungal Disease in Patients With Hematological Diseases
Zhang, S., Zhang, P., Wang, Z., Liu, L., He, Y., Jiang, E., Wei, J., Yang, D., Zhang, R., Zhai, W., et al. (2019) · Future Microbiology · doi:10.2217/fmb-2018-0344 · Cited by 7
Treatment options in emerging mold infections
Muñóz, P., Guinea, J., & Bouza, E. (2008) · Current Infectious Disease Reports · doi:10.1007/s11908-008-0077-9 · Cited by 7
Design, Synthesis, and Biological Activity Evaluation of Deuterated Diphenyl Azole Alcohol-Based CYP51 Inhibitors
Sun, Y., Luo, Z., Li, K., Wang, H., Gao, Z., Zhang, J., Liu, R., Liu, R., Wu, X., Liu, N., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01068 · Cited by 6
Treatment of fungal infections in adult pulmonary and critical care patients
LIMPER, A. H., Knox, K. S., Sarosi, G. A., Ampel, N. M., Bennett, J. E., Catanzaro, A. C., Davies, S. F. M., Dismukes, W. E., Hage, C. A., Marr, K. A., et al. (2011) · PULMONOLOGIYA · doi:10.18093/0869-0189-2011-0-3-9-52 · Cited by 6
Modulatory effect of voriconazole on the production of proinflammatory cytokines in experimental cryptococcosis in mice with severe combined immunodeficiency
Silva, E. G., Silva, S. M. D. S., Paula, C. R., Ruiz, L. D. S., & Dias, A. L. T. (2017) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2017.11.008 · Cited by 6
Therapeutic drug monitoring for antifungal triazoles: pharmacologic background and current status
Groll, A. H., & Gastine, S. (2019) · Handbook of analytical separations · doi:10.1016/b978-0-444-64066-6.00009-5 · Cited by 7
Efficacy of voriconazole and amphotericin B in corneal preservative media
Das, S., Mitra, S., Garg, P., Mallick, A., Priyadarshini, S. R., & Sharma, S. (2021) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1365_21 · Cited by 6
“,[18] MIC90 for voriconazole and amphotericin B for Aspergillus flavus and Fusarium solani was 2 μg/mL each for both the drugs, and for Candida albicans, it was 0.”
BackgroundMethod
Eumycetoma of the Hand Caused by Leptosphaeria tompkinsii and Refractory to Medical Therapy with Voriconazole
Cartwright, K. E., Clark, T. W., Hussain, A., Wiselka, M. J., Borman, A. M., & Johnson, E. M. (2011) · Mycopathologia · doi:10.1007/s11046-011-9432-8 · Cited by 6
“The newer triazole agents voriconazole and posaconazole may have improved efficacy and tolerability [21, 22] and are emerging as the agents of choice in eumycetoma although their high cost is likely to be prohibitive in developing countries [23, 24].”
Background
Müeller-Hinton methylene blue media as an alternative to RPMI 1640 for determining the susceptibility ofCryptococcus neoformansandCryptococcus gattiito posaconazole with Etest
Alvarado-Ramírez, E., Torres-Rodrı́guez, J. M., Murciano, F., & Sellart-Altisent, M. (2009) · Mycoses · doi:10.1111/j.1439-0507.2008.01678.x · Cited by 6
Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles
Dellacasa, C. M., Busca, A., Audisio, E., Marmont, F., Barbui, A. M., Falda, M., Rosa, F. G. D., Frairia, C., Allione, B., D’Ardìa, S., et al. (2013) · Journal of Chemotherapy · doi:10.1179/1973947813y.0000000142 · Cited by 6
Evaluación mediante tres técnicas de susceptibilidad a fluconazol en especies de Candida aisladas en pacientes con infecciones invasoras: Bogotá - Colombia
D, N. A. T., Álvarez, C., & S, M. A. R. (2009) · Revista chilena de infectología · doi:10.4067/s0716-10182009000200004 · Cited by 6
Isolation of Candida Species from Gastroesophageal Lesions among Pediatrics in Isfahan, Iran: Identification and Antifungal Susceptibility Testing of Clinical Isolates by E-test
Salehi, F., Esmaeili, M., & Mohammadi, R. (2017) · Advanced Biomedical Research · doi:10.4103/2277-9175.213662 · Cited by 6
Pattern of susceptibility to azoles by E test method in candidemia patients
Sri Wahyuni Gayatri, B., Premamalini, T., Rajyoganandh, S. V., & Kindo, A. J. (2015) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20150337 · Cited by 6
“From the perspective of antifungal resistance, Candida glabrata and Candida krusei are clearly the Candida species with the greatest potential to acquire resistance to fluconazole and Itraconazole.22,24 All the Candida species exhibited a very good activity against voriconazole except for one isolate of Candida albica…”
BackgroundInfluential
The Role of Second-Generation Antifungal Triazoles for Treatment of the Endemic Mycoses
Freifeld, A. G., Bariola, J. R., & Andes, D. R. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0133-0 · Cited by 6
Use of posaconazole for treatment of disseminated protothecosis in a dog
Enders, B. D., Olby, N. J., & Mariani, C. L. (2016) · Veterinary Record Case Reports · doi:10.1136/vetreccr-2016-000350 · Cited by 5
Resistance of filamental fungi in opportunistic mycoses: literature review
Rodrigues, M. C., Araújo, W. A. F., de Oliveira, I. M., Lana, D. F. D., & Carneiro, G. K. M. (2022) · Research Society and Development · doi:10.33448/rsd-v11i4.26198 · Cited by 5
“In 2006, as reported by Sabatelli et al. (2006), resistant strains of non-albicans Candida begin to emerge, such as C. krusei and C. glabrata, and the occurrence of resistance in isolates of C. parapsilosis and C. tropicalis is also reported to a lesser extent (Berto et al., 2018).”
Background
Lipid-Centric Approaches in Combating Infectious Diseases: Antibacterials, Antifungals and Antivirals with Lipid-Associated Mechanisms of Action
Ostroumova, O. S., & Efimova, S. S. (2023) · Antibiotics · doi:10.3390/antibiotics12121716 · Cited by 7
Fungal infections in the critically ill
Dhillon, R. H., & Clark, J. (2011) · Trends in Anaesthesia and Critical Care · doi:10.1016/j.tacc.2011.05.007 · Cited by 4
In Vitro Susceptibilities of Non-albicans Candida Species to Echinocandins, Azoles, and Amphotericin B in Tokat, Turkey
Yenişehirli, G., Özveren, G., Yenişehirli, A., & Bulut, Y. (2018) · Jundishapur Journal of Microbiology · doi:10.5812/jjm.59404 · Cited by 5
Isolation and Identification of Fungi from Wounds and Burns of Human and Farm Animals
AL-Tameemi, H. A. A. N., & Khalaf, J. M. (2013) · The Iraqi Journal of Veterinary Medicine · doi:10.30539/ijvm.v37i2.1389 · Cited by 5
Endophthalmitis as the initial manifestation of invasive fusariosis in an allogeneic stem cell transplant patient: A case report
Kao, A. S., Cramer‐Bour, C., Kupsky, W. J., & Soubani, A. O. (2023) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2023.02.004 · Cited by 5
Acremonium Pneumonia Successfully Treated in Patient with Acute Myeloid Leukemia: A Case Report
Khostelidi, S. N. (2016) · Journal of Bacteriology & Mycology Open Access · doi:10.15406/jbmoa.2016.02.00036 · Cited by 5
In vitrointeractions of amantadine hydrochloride, R-(-)-deprenyl hydrochloride and valproic acid sodium salt with antifungal agents against filamentous fungal species causing central nervous system infection
Galgóczy, L., Tóth, L., Virágh, M., Papp, T., & Vágvölgyi, C. (2012) · Acta Biologica Hungarica · doi:10.1556/abiol.63.2012.4.8 · Cited by 5
Antifungal Therapy Strategies in Hematopoietic Stem-Cell Transplant Recipients: Early Treatment Options for Improving Outcomes
Chandrasekar, P. H., & Ljungman, P. T. (2008) · Transplantation · doi:10.1097/tp.0b013e318177de64 · Cited by 5
“The drug has limited activity against C. neoformans and molds such as Fusarium spp, Scedosporium spp, Zygomycetes, P. boydii, and dematiaceous molds (70).”
BackgroundInfluential
Isolated Renal Mucormycosis in a Transplantation Recipient
Hamdi, A., Mulanovich, V. E., Matin, S. F., Landon, G., Sircar, K., Tu, S., & Nieto, Y. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1969 · Cited by 5
Amphotericin B use in children: conventional and lipid-based formulations
Kuyucu, N. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.5 · Cited by 5
Metal (II) Complexes of Fluconazole: Thermal, XRD and Cytotoxicity Studies.
Ali, S. I., Lei, Z., Ali, M., Kojima, K. K. K., Ahmed, M., Peng, R., Yang, D., Haider, S. M., Ayatollahi, S. A., & Chen, Z. (2020) · PubMed Central · doi:10.22037/ijpr.2020.1101142 · Cited by 6
Design, synthesis, and activity evaluation of novel tetrazole-based CYP51 inhibitors
Zhang, J., Liu, R., Sun, Y., Gao, Z., Liu, R., Luo, Z., Li, K., Wu, X., Hao, W., Liu, J., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109132 · Cited by 5
Intraocular penetration of liposomal amphotericin B after intravenous injection in inflamed human eyes
Ando, T., Kawakami, H., Mochizuki, K., Murata, K., Manabe, Y., Takagi, D., Yagasaki, A., Niwa, Y., Yamada, N., Ogura, S., et al. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.04.020 · Cited by 4
A Critical Review on the Dosing and Safety of Antifungals Used in Exotic Avian and Reptile Species
Visvanathan, N., Lim, J. Y. A., Chng, H. T., & Xie, S. (2023) · Journal of Fungi · doi:10.3390/jof9080810 · Cited by 5
Intravenous itraconazole against experimental neutropenic Candida parapsilosis infection: efficacy after suppression of bacterial translocation
Carrer, D.-P., Droggiti, D.-I., Τσαγανός, Θ., Pistiki, A. C., Samonis, G., & Giamarellos‐Bourboulis, E. J. (2013) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-013-0627-4 · Cited by 4
Prevalence and comparison for detection methods of Candida species in vaginal specimens from pregnant and non pregnant Saudi women
Alakeel, R. A., El-Kersh, T. A., Al‐Sheikh, Y. A., & Alahmadey, Z. Z. (2013) · World Academy of Science, Engineering and Technology, International Journal of Biotechnology and Bioengineering · Cited by 4
Single oral or intravenous administration of voriconazole achieved recommended therapeutic minimum inhibitory concentrations against Aspergillus in the common raven (Corvus corax)
Johnson, S. D., Buchweitz, J. P., & Lehner, A. F. (2022) · American Journal of Veterinary Research · doi:10.2460/ajvr.22.03.0055 · Cited by 4
Potential Original Drug for Aspergillosis: In Vitro and In Vivo Effects of 1-N,N-Dimethylamino-5-Isocyanonaphthalene (DIMICAN) on Aspergillus fumigatus
Szigeti, Z. M., Tálas, L., Széles, A., Hargitai, Z., Nagy, Z. L., Nagy, M., Kiss, A., Kéki, S., & Szemán-Nagy, G. (2022) · Journal of Fungi · doi:10.3390/jof8100985 · Cited by 4
Repurposing antifungals: population pharmacokinetics of itraconazole and hydroxy-itraconazole following administration of a nanocrystal formulation
Jansen, A. M. E., ter Heine, R., Donnelly, J. P., Blijlevens, N. M. A., & Brüggemann, R. J. M. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad072 · Cited by 4
Case report: A case of pulmonary mucormycosis caused by Rhizopus azygosporus infection complicated by type 2 diabetes mellitus
Wang, L., Qu, Y., Tang, L., Li, Y., Liu, L., & Liu, Y. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1240436 · Cited by 4
Candida hellenica var. hellenica as a possible cause of respiratory infection in a child with acute myeloid leukemia
Ioakimidou, A., Vyzantiadis, T., Tragiannidis, A., Arabatzis, M., Papageorgiou, T., Velegraki, A., Athanassiadou, F., & Malissiovas, N. (2011) · Medical Mycology · doi:10.3109/13693786.2011.561504 · Cited by 4
Use of Fungal Diagnostics and Therapy in Pediatric Cancer Patients in Resource-Limited Settings
Mukkada, S. T., Kirby, J., Apiwattanakul, N., Hayden, R. T., & Caniza, M. A. (2016) · Current Clinical Microbiology Reports · doi:10.1007/s40588-016-0038-2 · Cited by 4
First reported case of Gilbertella persicaria in human stool: outcome of a community study from Segamat, Johor, Malaysia
Huët, M. A. L., Wong, L. W., Goh, C. B. S., Ong, K. S., Dwiyanto, J., Reidpath, D. D., Lee, S. M., Rahman, S., & Tan, J. B. L. (2020) · Brazilian Journal of Microbiology · doi:10.1007/s42770-020-00323-z · Cited by 4
Therapeutic efficacy of posaconazole against Candida glabrata in a murine model of vaginitis
González, G. M., Elizondo-Zertuche, M., Garza‐González, E., & González‐González, J. G. (2009) · Mycoses · doi:10.1111/j.1439-0507.2009.01775.x · Cited by 4
Treatment options in emerging mold infections
Muñóz, P., Guinea, J., & Bouza, E. (2008) · Current Fungal Infection Reports · doi:10.1007/s12281-008-0012-4 · Cited by 4
Infectious Diseases in Pediatric Cancer
Koh, A. Y., & Pizzo, P. A. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3431-5.00027-3 · Cited by 4
Pharmacology of azole antifungal agents
Ashley, E. S. D. (2019) · CRC Press eBooks · doi:10.1201/9780429402012-12 · Cited by 4
Intravenous and Oral Posaconazole Pharmacokinetics in a Five-Year-Old With Mucor: A Case Report and Review of the Literature
Ruland, M. O., Egelund, T. A., Ng, J. S., Bradfield, S. M., & Egelund, E. F. (2019) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-24.6.528 · Cited by 4
Systemic Antifungals
Oak, A. S. W., Baddley, J. W., & Elewski, B. E. (2018) · Springer eBooks · doi:10.1007/978-3-319-66884-0_40 · Cited by 4
The efficacy and safety of first-line monotherapies in primary therapy of invasive aspergillosis: a systematic review
Chen, Y., Zhao, J., Wang, Y., Ge, L., Kwong, J. S.-W., Lan, J., Zhang, R., Zhao, H., Hu, L., Wang, J., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1530999 · Cited by 3
Bioactive Potential of Streptomyces Spp. Against Diverse Pathogenic Fungi
Harsha, H., Kumar, M., Kumar, P., Solanki, R., & Kapur, M. K. (2024) · Springer eBooks · doi:10.1007/978-981-97-5165-5_21 · Cited by 3
Usage of Antifungal Agents in Pediatric Patients Versus Adults: Knowledge and Gaps
Kourti, M., & Roilides, E. (2024) · Mycopathologia · doi:10.1007/s11046-024-00896-5 · Cited by 3
“It also has fungistatic activities against Candida, Coccidioides, selected Fusarium spp., Histoplasma , Scedosporium and Muc-orales [30].”
Invasive intracerebral fungal infection in a leukaemic patient
O'Brien, D., Lim, C. H., Farrell, M., O'Marcaigh, A. S., Rawluk, D. J. R., Fitzpatrick, F., & Smyth, E. G. (2011) · British Journal of Neurosurgery · doi:10.3109/02688697.2011.633638 · Cited by 3
Kolliphor® HS 15-cyclodextrin Complex for the Delivery of Voriconazole: Preparation, Characterization, and Antifungal Activity
Li, Y., Zhu, C., Wu, H., Pan, H., & Liu, H. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200520085915 · Cited by 3
Advances in pediatric antimicrobial agents development
Wood, J. B., Cravens, L. B., & Creech, C. B. (2018) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000713 · Cited by 3
Sensibilidad in vitro de hongos miceliales de aislamientos clínicos en pacientes con cáncer en el Instituto Nacional de Cancerología ESE
Chavez, J., Rivas, P., Cortés, J. A., Cuervo, S. I., Sánchez, R., & Parra‐Giraldo, C. M. (2010) · Infectio · doi:10.1016/s0123-9392(10)70129-6 · Cited by 3
Antifungal Host Defense Peptides
Lohner, K., & Leber, R. (2016) · Springer eBooks · doi:10.1007/978-3-319-32949-9_2 · Cited by 3
Pharmacology of Azole Antifungal Agents
Ashley, E. D. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-13 · Cited by 3
The Zygomycetes
Dannaoui, É., & Garcia‐Hermoso, D. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6397-8_7 · Cited by 3
Breakpoints for posaconazole susceptibility testing: background and discussion about the need of establishing values
Fleck, R., & Hof, H. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01568.x · Cited by 3
Future Treatments for Onychomycosis
Gupta, A., & Versteeg, S. G. (2018) · doi:10.1002/9781119226512.ch20 · Cited by 3
The Brief Case: Cutaneous ulceration associated with acalabrutinib treatment
Luzarraga, V., Nourrisson, C., Anglade, F., Chevenet, C., Poirier, P., & Moniot, M. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.01583-24 · Cited by 2
Successful multimodal treatment of Paecilomyces lilacinus infection in a dog
Espadale, E., Buckley, L. M., Borio, S., McEwan, N. R., & Schmidt, V. M. (2018) · Veterinary Record Case Reports · doi:10.1136/vetreccr-2018-000627 · Cited by 2
Antifungal Susceptibility of Candida Species Isolated from Urine from Patients in a Neurosciences Intensive Care Unit
Rath, S., Behera, I. C., & Sahu, M. C. (2018) · Apollo Medicine · doi:10.4103/am.am_43_18 · Cited by 2
Hyalohyphomycosis: Infection Due to Hyaline Moulds
Hospenthal, D. R. (2015) · Springer eBooks · doi:10.1007/978-3-319-13090-3_11 · Cited by 2
The tablet formulation of posaconazole: clinical pharmacology and the use in patients with hematologic malignancies
Veselov, A. V. (2020) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2020.2.96-117 · Cited by 2
Posaconazole (Noxafil), an Extended-Spectrum Oral Triazole Antifungal Agent
Chang, M., & Chagan, L. (2008) · PubMed Central · Cited by 2
A rare case of subcutaneous zygomycosis on the neck of an immunocompetent patient
Avendaño, M. V., Contreras, S. A., Dhoble, C. Y., Camacho, A. R., Perez, M. M., & Amari, K. R. (2015) · Case Reports in Internal Medicine · doi:10.5430/crim.v2n3p57 · Cited by 2
Antifungal Agents in Current Pediatric Practice
Cecinati, V., Perillo, T., Brescia, L. P., & Russo, F. G. (2013) · Current Infectious Disease Reports · doi:10.1007/s11908-013-0337-1 · Cited by 2
The role of second-generation triazole antifungal agents voriconazole and posaconazole in patients with hematologic malignancies
Bow, E. J., & Bacteriol, D. (2009) · Current Fungal Infection Reports · doi:10.1007/s12281-009-0005-y · Cited by 2
“Posaconazole has, in vitro, been more active than either amphotericin B or voriconazole against Aspergillus species; however, the clinical relevance of this observation is not known [ 11 ,12].”
Background
Drug Interaction Profile of Posaconazole
Leung, S., & Poulakos, M. N. (2008) · Internet Journal of Allied Health Sciences and Practice · doi:10.46743/1540-580x/2008.1196 · Cited by 2
Case of a diabetic man cured from rhinocerebral zygomycosis
Lakatos, B., Nikolova, R., Ocskay, L., Csomor, J., & Prinz, G. (2010) · Orvosi Hetilap · doi:10.1556/oh.2010.28969 · Cited by 2
Polyenes for prevention and treatment of invasive fungal infections
Drew, R. H. (2019) · CRC Press eBooks · doi:10.1201/9780429402012-10 · Cited by 2
Analysis of Pharmacokinetic/Pharmacodynamic Parameters and Dosage Regimen of Posaconazole against Candida spp. and Aspergillus spp. Using Monte Carlo Simulation
Wang, Y., Zhao, J., Hu, J., Zhao, X., & Yao, Y. (2020) · Pharmacology & Pharmacy · doi:10.4236/pp.2020.111003 · Cited by 2
“Posaconazole is categorized as a broad-spectrum triazole antifungal agent with potent in vitro and in vivo activities against a large number of clinically important yeasts and models [4] [5].”
Background
Features of antifungal therapy during long-lasting infectious process: a clinical case of fungal keratitis and profile of antifungal sensitivity based on assessing biofilm formation
Илнуровна, В. Р., Lisovskaya, S. А., Mayanskaya, K. A., Samigullin, D. V., & Isaeva, G. S. (2021) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-foa-1495 · Cited by 2
“solani обладает наибольшей устойчивостью [25, 29, 31, 32].”
Azoles
Andes, D. R., & Dismukes, W. E. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_5 · Cited by 3
Study into selected antimicrobial drugs for koalas (Phascolarctos cinereus), incorporating consideration of koalas’ endogenous plasma and serum antibacterial activity
Gharibi, S. (2018) · The Sydney eScholarship Repository (The University of Sydney) · Cited by 2
Intravenous posaconazole: key features of clinical pharmacology and practical applications
Veselov, A. V., & Климко, Н. Н. (2022) · Oncohematology · doi:10.17650/1818-8346-2022-17-2-121-133 · Cited by 1
Mucormycosis: Issues, Pathophysiology, Diagnosis and Treatment
Regmi, S., & Mahato, P. L. (2023) · Journal of Karnali Academy of Health Sciences · doi:10.61814/jkahs.v6i1.521 · Cited by 1
Evaluation of Posaconazole Therapeutic Drug Monitoring for Antifungal Prophylaxis in Hematology Patients at a Tertiary Referral Center
Ashok, A., Fernando, S. S., Lee, S. J., Coutsouvelis, J., Mangalore, R. P., & Morrissey, C. O. (2025) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001425 · Cited by 1
Invasive periodic multivisceral aspergillosis in HIV-infected patient with normal CD4+ cell count
Hasseine, L., Roger, P., Novellas, S., Salvador, F. D., Dunyach‐Remy, C., Bertout, S., & Gari-Toussaint, M. (2011) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2011.03.005 · Cited by 1
Prevention and Management of Infectious Complications in Kidney Transplant Recipients
Santos, R. D., & Brennan, D. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0342-9_27 · Cited by 1

Authors: Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., & McNicholas, P. M.
Affiliations: Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
ORCID: Mann, P. A.
Venue: Antimicrobial Agents and Chemotherapy
Publisher: American Society for Microbiology
Published: 2006-06
Volume: 50
Issue: 6
Pages: 2009-2015
ISSN: 0066-4804 (ISSN-L)
1098-6596
DOI: 10.1128/aac.00163-06
OpenAlex: W2139126851
Cited by: 491
References: 38
Citations by year: 2026: 8 · 2025: 13 · 2024: 8 · 2023: 8 · 2022: 13 · 2021: 16 · 2020: 17 · 2019: 16 · 2018: 37 · 2017: 20 · 2016: 21 · 2015: 26 · 2014: 33 · 2013: 23 · 2012: 27
FWCI: 28.15
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Antimicrobial Agents and Chemotherapy (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
Keywords: posaconazole, fluconazole, itraconazole, voriconazole, amphotericin B, antifungal susceptibility, minimum inhibitory concentration, molds, yeast, Candida, Cryptococcus, Aspergillus, Zygomycetes, triazole antifungals, antifungal resistance, in vitro antifungal activity
MeSH terms: Amphotericin B, Antifungal Agents, Aspergillosis, Aspergillus, Candida, Candidiasis, Cryptococcosis, Cryptococcus, Fungi, Humans, Microbial Sensitivity Tests, Mycoses, Pyrimidines, Triazoles, Fluconazole, Itraconazole, Drug Resistance, Fungal, Voriconazole, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks